Overview

Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

A prospective study to determine the metabolic effects of the contraceptive vaginal ring among overweight and obese women with polycystic ovary syndrome (PCOS). We will recruit a total of 40 participants and study use of the vaginal ring over a 4-month period.

Phase:

Phase 4

Details

Lead Sponsor:

Andrea Roe, MD, MPH

Treatments:

Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Ethinyl Estradiol
Etonogestrel
NuvaRing
Polyestradiol phosphate